Cannabinoids for Anxiety and Depression

Name: Cannabinoids for Anxiety and Depression
Uploaded: 2024-08-19 17:07:29
Description: Unlock the potential of cannabinoids in mental health with our in-depth webinar, “Cannabinoids for Anxiety and Depression.” This cutting-edge session is designed for licensed healthcare professionals seeking to expand their expertise in the application of cannabinoid therapies for mood disorders.

Education Webinars Cannabinoids for Anxiety and Depression

Integrate Powerful Hemp Cannabinoids into your Healthcare Practice

Learn from leading cannabis clinician Bonni Goldstein, MD and grow your practice revenues through our lab-tested hemp extract marketplace, while providing an exclusive medical discount to your patients. For a limited time, our platform is free for licensed US healthcare practitioners only.

With your free account, you'll get access to this educational video and so much more!

Learn more Create your free account

Cannabinoids for anxiety and depression:

Unlock the potential of cannabinoids in mental health with our in-depth webinar, “Cannabinoids for Anxiety and Depression.” This cutting-edge session is designed for licensed healthcare professionals seeking to expand their expertise in the application of cannabinoid therapies for mood disorders. This webinar promises a comprehensive, evidence-based approach to integrating cannabinoids into your practice for improved patient outcomes.

Dive deep into the mechanisms of cannabinoids, including the endocannabinoid system's role in mood regulation and the pharmacokinetics of various cannabinoid compounds.
Review the latest preclinical research and clinical trials on the efficacy and safety of cannabinoids in treating anxiety and depression, with an emphasis on real-world applications, patient outcomes, and safety.
Learn how to tailor cannabinoid treatments to individual patient profiles, considering factors such as dosage, cannabinoid ratios, and method of administration.

View Sources

Berger, M., et al. "Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial." The Journal of clinical psychiatry 83.5 (2022): 42111.

Choi, K., et al. Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J. Psychiatr. Res. 2012, 46, 882–889.

Cuttler, C., et al. "A naturalistic examination of the perceived effects of cannabis on negative affect." Journal of affective disorders 235 (2018): 198-205.

Cuttler, C., et al. "Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial." Scientific Reports 14.1 (2024): 16163.

deRoon-Cassini, T., et al. "Meet your stress management professionals: the endocannabinoids." Trends in molecular medicine 26.10 (2020): 953-968.

Gundugurti, P., et al. "Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial." Asian Journal of Psychiatry 97 (2024): 104073.

Habib, A., et al. "Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity." British journal of anaesthesia 123.2 (2019): e249-e253.

Hen-Shoval, D., et al. "Cannabinoid receptor 2 blockade prevents anti-depressive-like effect of cannabidiol acid methyl ester in female wky rats." International journal of molecular sciences 24.4 (2023): 3828.

Hill, M., et al. "Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report." Pharmacopsychiatry 41.02 (2008): 48-53.

Hill, M., et al. "Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress." Psychoneuroendocrinology 34.8 (2009): 1257-1262.

Hill, M., et al. "Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents." Journal of neural transmission 115 (2008): 1673-1679.

Hungund, B.L., et al. Upregulation of CB1 receptors and agonist-stimulated [35S] GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry 2004, 9, 184–190.

Koethe, D., et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural Transm. 2007, 114, 1055–1063.

Kuhathasan, N., et al. "An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample." BMC psychiatry 22.1 (2022): 303.

Martin, E., et al. "Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial." Frontiers in psychiatry 12 (2021): 729800.

Mato, S., et al. Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders. Biochem. Pharmacol. 2018, 157, 258–265.

Mechtler, L., et al. "The Use of Medical Cannabis in the Treatment Comorbid Anxiety and Depression (4674)." Neurology 96.15_supplement (2021): 4674.

Morena, M., et al. "Neurobiological interactions between stress and the endocannabinoid system." Neuropsychopharmacology 41.1 (2016): 80-102.

Navarro, D., et al. "Molecular alterations of the endocannabinoid system in psychiatric disorders." International journal of molecular sciences 23.9 (2022): 4764.

Russo, E., et al. "Survey of patients employing cannabigerol-predominant cannabis preparations: perceived medical effects, adverse events, and withdrawal symptoms." Cannabis and Cannabinoid Research 7.5 (2022): 706-716.

Vinod, K.Y.., et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol. Psychiatry 2005, 57, 480–486.

Walsh, Z., et al. "Medical cannabis and mental health: A guided systematic review." Clinical psychology review 51 (2017): 15-29.

Collapse